Oppenheimer analyst Jeff Jones downgraded Ventyx Biosciences (VTYX) to Perform from Outperform without a price target after after Eli Lilly entered an agreement to acquire all outstanding shares of Ventyx for $14 in cash.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VTYX:
- Hold Rating Maintained on Eli Lilly’s Acquisition of Ventyx Biosciences Amid Limited Upside and NLRP3 Uncertainty
- Ventyx Biosciences downgraded to Neutral from Buy at H.C. Wainwright
- Ventyx Biosciences downgraded to Neutral from Buy at UBS
- Ventyx Biosciences downgraded to Hold from Buy at Canaccord
- Ventyx downgraded to Market Perform from Outperform at LifeSci Capital